Analysis Note

Complete activation from homogeneous prothrombin by SDS-PAGE

General description

Designed for use in thrombin clotting time tests. Key enzyme that activates factor XIII and converts fibrinogen into fibrin.

Designed for use in thrombin clotting time tests. Serine protease formed in the plasma during the clotting process from prothrombin, calcium, and thromboplasmin. Acts on the soluble plasma protein fibrinogen to convert it to an insoluble fibrin clot. Prepared from homogenous human prothrombin by activation with Factor Xa, Factor Va, and phospholipid. Designed for use in thrombin time tests.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Forsberg, G., et al. 1992. J. Protein Chem.11, 201.Garcia, J.G. 1992. J. Lab. Clin. Med.120, 513.Scarborough, R.M., et al. 1992. J. Biol. Chem.267, 13146.Weigel, L.M., et al. 1992. Infect. Immun.60, 1568.

Packaging

1000, 5000 u in Plastic ampoule

100 u in Glass bottle

Physical form

Lyophilized from 200 mM NaCl, 50 mM sodium citrate, 0.1% PEG-8000, pH 6.5.

Preparation Note

Prepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Unit Definition

One unit is determined by comparison with a standard curve prepared using the Bureau of Biologics standard thrombin.

Warning

Toxicity: Harmful (C)